Pharmaceutical perspectives of impaired wound healing in diabetic foot ulcer
Authors:
- 13 July 2016
- journal article
- review article
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 46 (5) , 403-423
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Trade, Industry and Energy ((10047890)
This publication has 115 references indexed in Scilit:
- Stem cells conditioned medium: a new approach to skin wound healing managementCell Biology International, 2013
- Longer action means better drug: Tuning up protein therapeuticsBiotechnology Advances, 2011
- Benefit-Risk Assessment of Becaplermin in the Treatment of Diabetic Foot UlcersDrug Safety, 2010
- Mesenchymal stem cell-conditioned medium accelerates skin wound healing: An in vitro study of fibroblast and keratinocyte scratch assaysExperimental Cell Research, 2010
- The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary resultsInternational Wound Journal, 2009
- Apligraf in the Treatment of Neuropathic Diabetic Foot UlcersThe International Journal of Lower Extremity Wounds, 2009
- Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound HealingPLOS ONE, 2008
- Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of α‐smooth muscle actin, leading to reduction of wound contractionWound Repair and Regeneration, 2007
- Topical Vascular Endothelial Growth Factor Accelerates Diabetic Wound Healing through Increased Angiogenesis and by Mobilizing and Recruiting Bone Marrow-Derived CellsThe American Journal of Pathology, 2004
- The stimulation of epidermal proliferation by a specific protein (EGF)Developmental Biology, 1965